Article
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.
Leukemia - 1 Jan 2016
Stein H, Bob R, Dürkop H, Erck C, Kämpfe D, Kvasnicka H-M, Martens H, Roth A, Streubel A
Abstract excerpt
Recent advances in the diagnostic of myeloproliferative neoplasms (MPNs) discovered CALRETICULIN (CALR) mutations as a major driver in these disorders. In contrast to JAK2 mutations being mainly associated with polycythaemia vera, CALR mutations are only associated with primary myelofibrosis (PMF) and essential thrombocythaemia (ET). CALR mutations are present in the majority of PMF and ET patients lacking JAK2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.